General American Investors’s Corbus Pharmaceuticals CRBP Stock Holding History

General American Investors’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-20,000	Closed	-$1.08M	–	69
2020 Q3	$1.08M	Sell	20,000 -3,747	-16%	-$679K	0.12%	66
2020 Q2	$5.98M	Hold	23,747	–	–	0.76%	40
2020 Q1	$3.73M	Buy	23,747 +2,667	+13%	+$451K	0.51%	43
2019 Q4	$3.45M	Buy	21,080 +2,500	+13%	+$369K	0.32%	56
2019 Q3	$2.71M	Hold	18,580	–	–	0.27%	61
2019 Q2	$3.86M	Hold	18,580	–	–	0.37%	59
2019 Q1	$3.87M	Buy	+18,580	New	+$4.1M	0.38%	58

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

General American Investors's CRBP Position: Q4 2020 in Review

General American Investors sold out of Corbus Pharmaceuticals (CRBP) in Q4 2020, closing a stake of 20,000 shares — an estimated $1.08M sold.

General American Investors first reported a position in CRBP in Q1 2019 and held it in 7 quarters. The position peaked at $5.98M in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q4 2020.

General American Investors reported no remaining Corbus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
General American Investors sold 20,000 Corbus Pharmaceuticals shares in Q4 2020, an estimated $1.08M.
General American Investors first reported a position in Corbus Pharmaceuticals in Q1 2019 and held it in 7 quarters.
General American Investors's Corbus Pharmaceuticals position peaked at $5.98M in Q2 2020.
107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2020.

Based on General American Investors's 13F filing for Q4 2020, filed 12 Feb 2021.